Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 12;15(1):e33691.
doi: 10.7759/cureus.33691. eCollection 2023 Jan.

Comparing Gefitinib and Traditional Chemotherapy for Better Survival in Patients With Non-Small Cell Lung Cancer: A Systematic Review

Suthasenthuran Kanagalingam  1 , Zargham Ul Haq  2 , Nishok Victory Srinivasan  3 , Aujala Irfan Khan  4 , Ghadi D Mashat  5 , Mohammad Hazique  1 , Kokab Irfan Khan  4 , Prasana Ramesh  1 , Safeera Khan  1
Affiliations
Review

Comparing Gefitinib and Traditional Chemotherapy for Better Survival in Patients With Non-Small Cell Lung Cancer: A Systematic Review

Suthasenthuran Kanagalingam et al. Cureus. .

Abstract

Current non-small cell lung cancer (NSCLC) treatment consists of various combinations of surgery, chemotherapy, and/or radiation, depending on the tumor stage. Individuals with stage II-IIIa NSCLC undergo surgery, followed by combination chemotherapy containing cisplatin, such as vinorelbine + cisplatin. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, act by inhibiting any signaling pathway containing the EGFR mutation and inhibiting the growth of NSCLC. TKI is a treatment option in advanced NSCLC, resulting in more prolonged progression-free survival (PFS). This manuscript aims to evaluate the influence of utilizing gefitinib - either alone or in combination with conventional chemotherapeutic drug regimens upon NSCLC patient profile survival parameters. A systematic literature review was conducted across multiple scientific literature repositories. The review was performed using the preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2020. There were six randomized clinical trials (RCT) and five retrospective studies. The overall consensus based on the end outcome of each published journal on the effectiveness of gefitinib as a treatment option for NSCLC indicated that there was a notable difference in overall survival (OS) and progression-free survival (PFS) and disease-free survival (DFS) datasets. Gefitinib use correlated with increased timeframes for multiple patient survival parameters within articles shortlisted in this investigation. However, more comprehensive investigations are required to validate such correlations. Gefitinib did demonstrate the potential to provide beneficial effects and counteract NSCLC within such patients.

Keywords: epidermal growth factor receptor gene mutation; gefitinib; lung cancer; non-small cell lung carcinoma (nsclc); tyrosine kinase receptor inhibitors.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2020
PMC: PubMed central
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Centers for disease control and prevention: An update on cancer deaths in the United States. [ Jul; 2022 ]. 2022. https://www.cdc.gov/cancer/dcpc/research/update-on-cancer-deaths https://www.cdc.gov/cancer/dcpc/research/update-on-cancer-deaths
    1. National Cancer Institute: Non-small cell lung cancer treatment (PDQ®)-health professional version. [ Jul; 2022 ]. 2022. https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq - PubMed
    1. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: Final overall survival analysis of CTONG1104 phase III trial. Zhong WZ, Wang Q, Mao WM, et al. J Clin Oncol. 2021;39:713–722. - PMC - PubMed
    1. The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. Goldstraw P, Chansky K, Crowley J, et al. J Thorac Oncol. 2016;11:39–51. - PubMed
    1. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. Bethune G, Bethune D, Ridgway N, Xu Z. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256436/ J Thorac Dis. 2010;2:48–51. - PMC - PubMed

LinkOut - more resources